Metsera, Inc.
MTSR
Clasificación en acciones
#2575
Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in... Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in crafting both injectable and oral nutrient-stimulated hormone analog peptides. These therapeutic compounds are primarily aimed at addressing obesity, overweight conditions, and associated health issues. Its developmental pipeline features MET-097i and MET-233i, both under investigation for treating obesity and overweight patients. Furthermore, Metsera is advancing a potential combination therapy involving MET-233i and MET-097i. The company is also progressing additional drug candidates, including MET-002, MET-224o, MET-067i, and MET-034i, all of which target disorders such as diabetes and obesity. Founded in 2022, Metsera, Inc. maintains its corporate headquarters in New York, New York.
Precio por acción
$70.50
Última sincronización: 2025-11-14
Capitalización bursátil
$7.33B
Cambio (1 día)
0.00%
Cambio (1 año)
33.60%
País
US
Comercio Metsera, Inc. (MTSR)
Categoría
Healthcare
Ratio P/S de Metsera, Inc. (MTSR)
Ratio P/S al 2026 TTM: 0
Según los informes financieros más recientes y el precio de las acciones de Metsera, Inc., el ratio P/S actual (TTM) es 0. Al final de 2026, el ratio P/S era 0.
Historial del ratio P/S de Metsera, Inc. desde 2026 hasta 2026
Ratio P/S al final de cada año
| Año | Ratio P/S | Cambiar |
|---|---|---|
| Not enough data for the provided dates. | ||
Ratio P/S de empresas similares o competidoras
| Empresa | Ratio P/S | Diferencia del ratio P/S | País |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| 10.15 | - |
NL
|
|
| - | - |
CH
|
